IBDEI2N8 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,44363,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,44363,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,44363,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,44364,0)
 ;;=C92.10^^200^2228^48
 ;;^UTILITY(U,$J,358.3,44364,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44364,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,44364,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,44364,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,44365,0)
 ;;=D47.1^^200^2228^49
 ;;^UTILITY(U,$J,358.3,44365,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44365,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,44365,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,44365,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,44366,0)
 ;;=C82.69^^200^2228^50
 ;;^UTILITY(U,$J,358.3,44366,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44366,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,44366,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,44366,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,44367,0)
 ;;=C82.60^^200^2228^51
 ;;^UTILITY(U,$J,358.3,44367,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44367,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,44367,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,44367,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,44368,0)
 ;;=D56.2^^200^2228^52
 ;;^UTILITY(U,$J,358.3,44368,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44368,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,44368,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,44368,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,44369,0)
 ;;=D75.9^^200^2228^53
 ;;^UTILITY(U,$J,358.3,44369,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44369,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,44369,1,4,0)
 ;;=4^D75.9
 ;;^UTILITY(U,$J,358.3,44369,2)
 ;;=^5002393
 ;;^UTILITY(U,$J,358.3,44370,0)
 ;;=D59.0^^200^2228^56
 ;;^UTILITY(U,$J,358.3,44370,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44370,1,3,0)
 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,44370,1,4,0)
 ;;=4^D59.0
 ;;^UTILITY(U,$J,358.3,44370,2)
 ;;=^5002323
 ;;^UTILITY(U,$J,358.3,44371,0)
 ;;=D59.2^^200^2228^57
 ;;^UTILITY(U,$J,358.3,44371,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44371,1,3,0)
 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,44371,1,4,0)
 ;;=4^D59.2
 ;;^UTILITY(U,$J,358.3,44371,2)
 ;;=^5002325
 ;;^UTILITY(U,$J,358.3,44372,0)
 ;;=R59.9^^200^2228^60
 ;;^UTILITY(U,$J,358.3,44372,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44372,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
 ;;^UTILITY(U,$J,358.3,44372,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,44372,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,44373,0)
 ;;=D47.3^^200^2228^61
 ;;^UTILITY(U,$J,358.3,44373,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44373,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,44373,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,44373,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,44374,0)
 ;;=C82.09^^200^2228^62
 ;;^UTILITY(U,$J,358.3,44374,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44374,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,44374,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,44374,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,44375,0)
 ;;=C82.00^^200^2228^63
 ;;^UTILITY(U,$J,358.3,44375,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44375,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Unspec Site
 ;;^UTILITY(U,$J,358.3,44375,1,4,0)
 ;;=4^C82.00
